Mesenchymal Stromal Cells: Bridging the Gaps in Hematologic Disease Therapy
Open Access
- 18 November 2025
- journal article
- review article
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (1) , 434-488
Abstract
Mesenchymal stromal cells (MSCs) have demonstrated therapeutic potential in hematologic diseases by modulating immune responses, supporting hematopoiesis, and remodeling the bone marrow microenvironment. Clinically, MSCs have been explored for graft-versus-host disease and hematopoietic stem cell transplantation support, while their applications in hematologic malignancies, including acute myeloid leukemia, multiple myeloma, and myelodysplastic syndromes, remain under investigation. However, therapeutic heterogeneity, safety concerns, and standardization challenges limit their clinical translation. Recent advances in MSC-derived extracellular vesicles, gene modification technologies, and integrative combination strategies have expanded the therapeutic landscape, enabling more precise and targeted modulation of immune responses and tumor microenvironments. Moreover, disease-specific evidence highlights the dual roles of MSCs—acting either as therapeutic agents or as contributors to disease progression—depending on stromal plasticity and niche conditioning. This review provides a comprehensive and mechanistic synthesis of MSC functions across both malignant and non-malignant hematologic disorders, integrating preclinical and clinical findings in immunoregulation, hematopoietic recovery, anti-fibrosis, and microenvironmental reprogramming. In addition, we critically evaluate emerging strategies to overcome translational bottlenecks, including inter-donor variability, lack of predictive potency markers, and the need for scalable, standardized manufacturing protocols. By bridging foundational mechanisms with translational potential, this review offers forward-looking perspectives to guide future optimization and clinical integration of MSC-based therapies in hematology. Graphical AbstractKeywords
Funding Information
- National Natural Science Foundation of China (No. 81873444, No. 82070213, and No.82370196)
- National Natural Science Foundation of China (No. 81873444, No. 82070213, and No.82370196)
- National Natural Science Foundation of China (No. 81873444, No. 82070213, and No.82370196)
- National Natural Science Foundation of China (No. 81873444, No. 82070213, and No.82370196)
- National Natural Science Foundation of China (No. 81873444, No. 82070213, and No.82370196)
This publication has 260 references indexed in Scilit:
- Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell TransplantJAMA Oncology, 2024
- Bone marrow‐derived mesenchymal stem cells inhibit NK cell function via Tim‐3/galectin‐9 in multiple myeloma patientsClinical and Translational Medicine, 2023
- CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell–induced natural killer–cell exhaustion in multiple myelomaClinical and Translational Medicine, 2022
- Acute Myeloid Leukemia Cells Educate Mesenchymal Stromal Cells toward an Adipogenic Differentiation Propensity with Leukemia Promotion CapabilitiesAdvanced Science, 2022
- Bone marrow‐mesenchymal stem cell‐derived extracellular vesicles affect proliferation and apoptosis of leukemia cells in vitroFEBS Open Bio, 2021
- Small‐sized mesenchymal stem cells with high glutathione dynamics show improved therapeutic potency in graft‐versus‐host diseaseClinical and Translational Medicine, 2021
- Mesenchymal stem cells enhance the impact of KIR receptor‐ligand mismatching on acute graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemiaHematological Oncology, 2021
- Research progress on exosomes derived from mesenchymal stem cells in hematological malignanciesHematological Oncology, 2020
- Exosomal sphingosine 1‐phosphate secreted by mesenchymal stem cells regulated Treg/Th17 balance in aplastic anemiaIUBMB Life, 2019
- Mesenchymal stem cells improve platelet counts in mice with immune thrombocytopeniaJournal of Cellular Biochemistry, 2019